Koss-Olinger Consulting’s Biogen BIIB Stock Holding History

Koss-Olinger Consulting’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,256	Closed	-$911K	–	276
2025 Q3	$911K	Hold	7,256	–	–	0.08%	128
2025 Q2	$911K	Sell	7,256 -42	-0.6%	-$5.23K	0.07%	128
2025 Q1	$999K	Buy	+7,298	New	+$1.04M	0.08%	119
2021 Q2	–	Sell	-3,608	Closed	-$1.01M	–	250
2021 Q1	$1.01M	Buy	+3,608	New	+$973K	0.17%	71

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Koss-Olinger Consulting's BIIB Position: Q4 2025 in Review

Koss-Olinger Consulting sold out of Biogen (BIIB) in Q4 2025, closing a stake of 7,256 shares — an estimated $911K sold.

Koss-Olinger Consulting first reported a position in BIIB in Q1 2021 and held it in 4 quarters. The position peaked at $1.01M in Q1 2021. 1,000 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.

Koss-Olinger Consulting reported no remaining Biogen position as of Q4 2025 after selling out during the quarter.
Koss-Olinger Consulting sold 7,256 Biogen shares in Q4 2025, an estimated $911K.
Koss-Olinger Consulting first reported a position in Biogen in Q1 2021 and held it in 4 quarters.
Koss-Olinger Consulting's Biogen position peaked at $1.01M in Q1 2021.
1,000 funds tracked by Wall St. Rank held Biogen as of Q4 2025.

Based on Koss-Olinger Consulting's 13F filing for Q4 2025, filed 10 Feb 2026.